Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Venla Ellilä, Jonna Levola, Alexander Denissoff, Markus Partanen & Solja Niemelä. (2023) Psychotic-Like Experiences and Concurrent Substance Use Among People Who Use New Psychoactive Substances. Substance Use & Misuse 58:12, pages 1606-1614.
Read now
Read now
Yasmin Schmid, Miguel Galicia, Severin B. Vogt, Matthias E. Liechti, Guillermo Burillo-Putze, Paul I. Dargan, Alison M. Dines, Isabelle Giraudon, Fridtjof Heyerdahl, Knut Erik Hovda, David M. Wood, Christopher Yates & Òscar Miró. (2022) Differences in clinical features associated with cannabis intoxication in presentations to European emergency departments according to patient age and sex. Clinical Toxicology 60:8, pages 912-919.
Read now
Read now
Collin Tebo, Maryann Mazer-Amirshahi, Paul Wax, Sharan Campleman, Edward Boyer, Jeffrey Brent, Amit Sheth, Raminta Daniuaityte & Robert Carlson. (2021) Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation. Journal of Psychoactive Drugs 53:3, pages 207-214.
Read now
Read now
Namkee G. Choi, C. Nathan Marti, Diana M. DiNitto & S. David Baker. (2021) Cannabis and synthetic cannabinoid poison control center cases among adults aged 50+, 2009–2019. Clinical Toxicology 59:4, pages 334-342.
Read now
Read now
Rikinkumar S. Patel, Hemant Goyal, Ritvij Satodiya & William E. Tankersley. (2020) Relationship of Cannabis Use Disorder and Irritable Bowel Syndrome (IBS): An Analysis of 6.8 Million Hospitalizations in the United States. Substance Use & Misuse 55:2, pages 281-290.
Read now
Read now
Adriana Joseph, Helen-Maria Lekas, Marc Manseau & Crystal Lewis. (2019) A Polydrug and Psychosocial Profile of Synthetic Cannabinoid Use in a New York City Community Sample, 2016–2017. Substance Use & Misuse 54:2, pages 282-287.
Read now
Read now
Murat Yalçın, Nazlı Tunalı, Handan Yıldız, Ayşenur Oğuz & Bülent Kadri Gültekin. (2018) Sociodemographic and clinical characteristics of synthetic cannabinoid users in a large psychiatric emergency department in Turkey. Journal of Addictive Diseases 37:3-4, pages 259-267.
Read now
Read now
V. Yu. Skryabin & M. A. Vinnikova. (2018) Clinical characteristics of synthetic cannabinoid-induced psychotic disorders: a single-center analysis of hospitalized patients. Journal of Addictive Diseases 37:3-4, pages 135-141.
Read now
Read now
Jane Carlisle Maxwell. (2018) The Changing Face of Synthetic Cannabinoids in Texas. Journal of Psychoactive Drugs 50:4, pages 281-286.
Read now
Read now
Articles from other publishers (17)
Thomas Coombs, Amor Abdelkader, Tilak Ginige, Patrick Van Calster, Matthew Harper, Dhiya Al-Jumeily OBE & Sulaf Assi. (2023) Understanding Drug Use Patterns Among the Homeless Population: A Systematic Review of Quantitative Studies. Emerging Trends in Drugs, Addictions, and Health, pages 100059.
Crossref
Crossref
David Barbic, Madelyn Whyte, Gurwinder Sidhu, Allesandra Luongo, Robert Stenstrom, Tapash Apu Chakraborty, Frank Scheuermeyer, William G. Honer & Daniel J. Lane. (2022) What is the risk of returning to the emergency department within 30 days for patients diagnosed with substance-induced psychosis?. Canadian Journal of Emergency Medicine 24:7, pages 702-709.
Crossref
Crossref
Melissa A. Jackson, Amanda L. Brown, Jennifer Johnston, Richard Clancy, Iain McGregor, Raimondo Bruno, Nick Lintzeris, Mark Montebello, Jennifer Luksza, Jenny Bowman, Nghi Phung, Dave Allsop & Adrian J. Dunlop. (2021) The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients. Journal of Cannabis Research 3:1.
Crossref
Crossref
Rob Ralphs, Paul Gray & Oliver B. Sutcliffe. (2021) The impact of the 2016 Psychoactive Substances Act on synthetic cannabinoid use within the homeless population: Markets, content and user harms. International Journal of Drug Policy 97, pages 103305.
Crossref
Crossref
Alexandra P. Lam, Sebastian Moeller, Christine Speitling, Martin C. Lam, Alexandra Philipsen & Helge H. O. Müller. (2020) Consumption of Synthetic Cannabinoids in Adult Attention-Deficit/Hyperactivity Disorder: a Pilot Study. International Journal of Mental Health and Addiction 19:5, pages 1586-1604.
Crossref
Crossref
Ritvij Satodiya & Nikhil Palekar. (2020) Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia. Cureus.
Crossref
Crossref
Melissa Hobbs, Rashmi Patel, Paul D Morrison, Nicola Kalk & James M Stone. (2020) Synthetic cannabinoid use in psychiatric patients and relationship to hospitalisation: A retrospective electronic case register study. Journal of Psychopharmacology 34:6, pages 648-653.
Crossref
Crossref
Yasmin Schmid, Irene Scholz, Laura Mueller, Aristomenis K. Exadaktylos, Alessandro Ceschi, Matthias E. Liechti & Evangelia Liakoni. (2020) Emergency department presentations related to acute toxicity following recreational use of cannabis products in Switzerland. Drug and Alcohol Dependence 206, pages 107726.
Crossref
Crossref
Laura Orsolini, Stefania Chiappini, Duccio Papanti, Domenico De Berardis, John M. Corkery & Fabrizio Schifano. (2019) The Bridge Between Classical and “Synthetic”/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective. Frontiers in Psychiatry 10.
Crossref
Crossref
Hina Akram, Claire Mokrysz & H Valerie Curran. (2019) What are the psychological effects of using synthetic cannabinoids? A systematic review. Journal of Psychopharmacology 33:3, pages 271-283.
Crossref
Crossref
Sai Krishna Tikka & Deepak Cyril D’Souza. 2019. Cannabis Use Disorders. Cannabis Use Disorders
127
155
.
Ziva D. Cooper & Arthur Robin Williams. 2019. Cannabis Use Disorders. Cannabis Use Disorders
103
111
.
Melissa Hobbs, Nicola J Kalk, Paul D Morrison & James M Stone. (2018) Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review. European Neuropsychopharmacology 28:12, pages 1289-1304.
Crossref
Crossref
Huiqiong Deng, Christopher D. Verrico, Thomas R. Kosten & David A. Nielsen. (2018) Psychosis and synthetic cannabinoids. Psychiatry Research 268, pages 400-412.
Crossref
Crossref
Joao P. De Aquino, Mohamed Sherif, Rajiv Radhakrishnan, John D. Cahill, Mohini Ranganathan & Deepak C. D’Souza. (2018) The Psychiatric Consequences of Cannabinoids. Clinical Therapeutics 40:9, pages 1448-1456.
Crossref
Crossref
Rachel Sutherland, Amy Peacock, Amanda Roxburgh, Monica J. Barratt, Lucinda Burns & Raimondo Bruno. (2018) Typology of new psychoactive substance use among the general Australian population. Drug and Alcohol Dependence 188, pages 126-134.
Crossref
Crossref
Huiqiong Deng, Satyajit Mohite, Robert Suchting, David A. Nielsen & Olaoluwa O. Okusaga. (2018) Impact of synthetic cannabinoid use on hospital stay in patients with bipolar disorder versus schizophrenia, or other psychotic disorders. Psychiatry Research 261, pages 248-252.
Crossref
Crossref